DOI QR코드

DOI QR Code

Short Low Concentration Cisplatin Treatment Leads to an Epithelial Mesenchymal Transition-like Response in DU145 Prostate Cancer Cells

  • Liu, Yi-Qing (Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Zhang, Guo-An (Department of The Morphology Laboratory, Jining Medical University) ;
  • Zhang, Bing-Chang (Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Wang, Yong (Department of Clinical Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Liu, Zheng (Department of Urology, Shandong Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Jiao, Yu-Lian (Department of Central Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Shandong University) ;
  • Liu, Ning (Department of Information Technology, Jining Medical University) ;
  • Zhao, Yue-Ran (Department of Central Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Shandong University)
  • Published : 2015.03.04

Abstract

Background: Prostate cancer is one of the main causes of cancer death, and drug resistance is the leading reason for therapy failure. However, how this occurs is largely unknown. We therrfore aimed to study the response of DU145 cells to cisplatin. Materials and Methods: Du145 prostate cancer cells were treated with a low dose of cisplatin for 24 h and cell viability and number were determined by MTT assay and trypan blue exclusion assay, respectively. The real time polymerase chain reaction (PCR) was used to assess responses to cisplatin treatment. Results: After 24h $2{\mu}g/ml$ treatment did not result in significant reduction in cell viability or number. However, it led to enhanced cancer cell invasiveness. E-cadherin mRNA was reduced, and vimentin, Snail, Slug, metalloproteinase 9 (MMP9) mRNA expression increased significantly, a feature of epithelial-mesenchymal transition (EMT). Conclusions: Short time low concentration cisplatin treatment leads to elevated invasiveness of DU145 cancer cells and this is possibly due to EMT.

Keywords

References

  1. Baribeau S, Chaudhry P, Parent S, et al (2014). Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One, 9, 86987. https://doi.org/10.1371/journal.pone.0086987
  2. D'Amico AV, Cote K, Loffredo M, et al (2002). Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol, 20, 4567-73. https://doi.org/10.1200/JCO.2002.03.061
  3. Du LB, Li HZ, Wang XH, et al (2014). Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev, 15, 5839-43. https://doi.org/10.7314/APJCP.2014.15.14.5839
  4. Florea AM, Büsselberg D (2011). Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel), 3, 1351-71. https://doi.org/10.3390/cancers3011351
  5. Gavert N, Ben-Ze'ev A (2008). Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Molecular Medicine, 14, 199-209. https://doi.org/10.1016/j.molmed.2008.03.004
  6. Han R-F, Ji X, Dong X-G, et al (2014). An epigenetic mechanism underlying doxorubicin induced EMT in the human BGC-823 gastric cancer cell. Asian Pac J Cancer Prev, 15, 4271-4. https://doi.org/10.7314/APJCP.2014.15.10.4271
  7. Han R, Xiong J, Xiao R, et al (2013). Activation of $\beta$-catenin signaling is critical for doxorubicin-induced epithelialmesenchymal transition in BGC-823 gastric cancer cell line. Tumor Biol, 34, 277-84. https://doi.org/10.1007/s13277-012-0548-3
  8. Hansen MB, Nielsen SE, Berg K (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunological Methods, 119, 203-10. https://doi.org/10.1016/0022-1759(89)90397-9
  9. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA: Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  10. Jung K-W, Won Y-J, Kong H-J, et al (2013). Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treatment, 45, 1-14. https://doi.org/10.4143/crt.2013.45.1.1
  11. Kalluri R, Weinberg RA (2009). The basics of epithelialmesenchymal transition. J Clin Invest, 119, 1420-8. https://doi.org/10.1172/JCI39104
  12. Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7, 573-84. https://doi.org/10.1038/nrc2167
  13. Lang BJ, Nguyen L, Nguyen HC, et al (2012). Heat stress induces epithelial plasticity and cell migration independent of heat shock factor 1. Cell Stress Chaperones, 17, 765-78. https://doi.org/10.1007/s12192-012-0349-z
  14. Latifi A, Abubaker K, Castrechini N, et al (2011). Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem, 112, 2850-64. https://doi.org/10.1002/jcb.23199
  15. Ruijter J, Ramakers C, Hoogaars W, et al (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res, 37, 45 https://doi.org/10.1093/nar/gkp045
  16. Siddik ZH (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22, 7265-79. https://doi.org/10.1038/sj.onc.1206933
  17. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  18. Strober W (2001). Trypan blue exclusion test of cell viability. Current protoc immunol, Appendix 3:Appendix 3B.
  19. Yue PY, Leung EP, Mak NK, et al (2010). A simplified method for quantifying cell migration/wound healing in 96-well plates. J Biomol Screen, 15, 427-33. https://doi.org/10.1177/1087057110361772

Cited by

  1. The relationship between platinum drug resistance and epithelial–mesenchymal transition vol.91, pp.2, 2017, https://doi.org/10.1007/s00204-016-1912-7